Product information:
| Product name |
Glibenclamide Tablets |
| Shelf life |
36 Months |
| Specification |
10 tablets/blister,10 blisters/box. |
| Storage |
Dry, dark and sealed |
Pharmacokinetics:
Oral absorption is fast, protein binding rate is very high, 95%, 2-5 hours after oral drug concentration reached the peak, lasting for 24 hours. The half-life is 10 hours. It is metabolized in the liver and excreted by the liver and kidney about 50% respectively.
Pharmacology and Toxicology:
This product is a hypoglycemic drug.
1. To stimulate insulin secretion of pancreatic islet β cells, the prerequisite is that islet β cells have certain function of insulin synthesis and secretion;
2. By increasing the level of portal vein insulin or directly acting on the liver, the glycogen decomposition and gluconeogenesis of the liver were inhibited, and the production and output of glucose in the liver were reduced;
3. It may also increase the sensitivity of extrapancreatic tissue to insulin and the utilization of glucose (mainly through post receptor effect). Therefore, the overall effect is to reduce fasting blood glucose and postprandial blood glucose.
Indication:
It is suitable for patients with mild to moderate non insulin dependent diabetes mellitus with unsatisfied curative effect of diet control alone.
Adverse reactions:
1. Diarrhea, nausea, vomiting, headache, stomachache or discomfort may occur;
2. Rash was rare;
3. Rare and serious jaundice, liver function damage, bone marrow suppression, granulocytopenia (manifested as sore throat, fever, infection), thrombocytopenia (bleeding, purpura), etc.
Taboo:
The following conditions should be disabled:
1. Type I diabetic patients;
2. Patients with type II diabetes had ketoacidosis, coma, severe burn, infection, trauma and major operation;
3. liver and kidney dysfunction;
4. Allergic to sulfonamides;
5. Patients with leukopenia.
Audited Supplier 
){kind=link}